KV Pharmaceutical enters into a consent decree with the FDA. As part of the consent decree, KV has agreed not to market products it manufactures until it has satisfied certain requirements designed to demonstrate compliance with FDA’s current good manufacturing practices (CGMP) regulations. KV has also agreed that it will not distribute certain products, including its prenatal vitamins and hematinic products, until the products are approved by FDA’s ANDA or NDA processes.
J&J cutting sales and marketing staff for biologics. Johnson & Johnson announced plans to cut 400 marketing and sales jobs to make up for lagging sales of its anemia drug Procrit. The cuts will be limited to the company’s two biologics groups—Centocor and Ortho Biotech. About 150 employees will be let go from Ortho, and the division will move from its New Jersey headquarters to Centocor’s offices in Horsham, PA.
AstraZeneca getting black marks on Seroquel marketing revelations. Burying studies not recommended. And contradictory messages in different countries definitely net recommended.
PLUS – the shuffling of MSLs into other roles/depts. From PharmaExec.com.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff